HLJ2 Effectively Ameliorates Colitis-Associated Cancer via Inhibition of NF-κB and Epithelial–Mesenchymal Transition

INTRODUCTION: Colitis-associated cancer (CAC) accounts for approximately 15% of IBD patient mortalities. However, currently available anti-CAC drugs possess many disadvantages including safety, specificity and side effects. Therefore, the development of novel anti-CAC compounds is imperative. HLJ2 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Song, Huachen, Tang, Xiaonan, Li, Xiang, Wang, Yufei, Deng, Anjun, Wang, Wenjie, Zhang, Haijing, Qin, Hailin, Wu, LianQiu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573331/
https://www.ncbi.nlm.nih.gov/pubmed/33116416
http://dx.doi.org/10.2147/DDDT.S262806

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7573331/
https://www.ncbi.nlm.nih.gov/pubmed/33116416
http://dx.doi.org/10.2147/DDDT.S262806

Ejemplares similares